We asked 2,172 researchers around the world what they thought of the announcement that Thermo Fisher Scientific is acquiring Life Technologies.  Less than 24 hours after the announcement roughly half of the participants (49%) were aware of the news.  The fact that this news has spread this quickly is a testament to the considerable impact this merger is likely…

Percepta:  Epigenetics has certainly been a hot topic.  We’re very glad to have a chance to speak with you and get your read on where the field is heading.  Now that the field has had a chance to develop, can you give our readers a brief summary of what is now encompassed in the field of epigenetics?

PJ:   Well that…

China remains an attractive market for life science tools suppliers capable of taking advantage…

Percepta: So, as the Editor of the Life Science Dashboards™ tell us what you have been working on lately.

SK: Well, we are going through some format changes to the Dashboard, including updating the brand and look and feel for 2013, and we’ve also improved the structure of the content somewhat. We’ve just completed a month-long audit of some of…

If you are looking for ways to communicate with researchers that identify themselves as immunology researchers, some of Percepta’s latest data suggests the popularity of various information sources spans a pretty broad spectrum. Search engines still rank high as a place immunologist look for product information. Also popular are peer recommendations, journal citations and company web sites, with more…

As has been shown again and again, seemingly homogeneous cell populations often consist of more than one cell type, which can confound research results. Single-cell research offers a bottom-up approach to circumventing such unwanted cellular heterogeneity. As a testament to its potential promise, the NIH has committed ~$90 million over 5 years to single cell analysis research. At Percepta,…

In February 2013 we polled our panel of fluorescent imaging reagent users regarding their anticipated laboratory budget. Data reveals that commercial users anticipate a slight increase compared to academic users. As shown in the table, 24.1% of commercial users of fluorescent imaging reagents expect their budget to increase over the next 12 months, vs. 17.6% of academic users (a…

If you thought cell therapy had suffered too many setbacks in recent years and was stuck in neutral – think again. In a recent Percepta poll of 250 randomly selected life science researchers working in biotechnology and pharmaceutical companies more than 20% are involved in projects focused on allogeneic or autologous cell therapy and/or regenerative medicine. Even more surprising…

It was a hectic close to 2010 which shows us that biotools industry is alive and healthy! Though the future economic environment for the globe remains uncertain and public funding levels for life sciences in the US may plataue of or even dip in 2011, there were several things that we noticed at Percepta that we believe will be…

In the recent few quarters Percepta has experienced an increase in demand for studies relating to better serving the pharmaceutical industry. The focus of the studies have varied considerably but the trend is evident. This tells us bio-tools companies are getting more serious about tailoring an offering to the drug discovery and development market that will resonate with the…